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Abstract
Background: It has been observed that the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors as compared to
the placebo groups in some clinical trials conducted in China is weaker than that in trials conducted outside China,
leading to the suspicion that this may be caused by differential Glycosylated Hemoglobin (HbA1c) response in the
placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries.
Methods: We searched published articles and other documents related to phase III placebo-control trials of DPP-4
inhibitors in Type 2 diabetes mellitus (T2DM). We included studies from different countries and compared those
conducted in China to those conducted in other countries. Meta-regression analysis was used to analyze the HbA1c
response in the placebo arms.
Results: A total of 66 studies met the inclusion criteria and 10 were conducted within China. There were a total of 8303
participants (mean age 56, male 57 %) in placebo groups. The pooled change in HbA1c for the placebo groups of 10
trials conducted in patients with T2DM in China was 0.26 % (95 % CI [-0.36 %, -0.16 %], p-value < 0.001), compared to
0.015 % (95 % CI [-0.05 %, 0.08 %], p-value is 0.637) for 56 trials conducted outside of China. The difference of placebo
effect between trials conducted in and outside China is -0.273 % (95 % CI [-0.42 %, -0.13 %], p-value is less than 0.001)
while after excluding trials conducted in Japan, the difference is -0.203 % (95 % CI [-0.35 %, -0.06 %], p-value is 0.005).
They are both statistically significant.
Conclusions: The meta-analysis in the article demonstrates that there is statistically significant difference in the HbA1c
response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries. This
differential HbA1c response in the placebo arm should be taken into consideration by both experimenters and medical
decision makers when future DPP-4 studies are conducted in China.
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Background
Diabetes has become one of the most threatening non-
infectious diseases. The prevention and treatment of
diabetes is very important in China because China may
have become a country with the largest number of
diabetes patients. Most of these patients have type 2
diabetes mellitus (T2DM) [1]. Dipeptidyl peptidase-4
(DPP-4) inhibitors are a class of oral antihyperglycemic
agents which has been proved to be better than some
traditional treatments in many aspects [2–4]. The
Guideline of Prevention and Treatment for T2DM in
China [5] published by Chinese Diabetes Society places
DPP-4 inhibitors second-line with metformin for com-
bination therapy if metformin for monotherapy cannot
control glycemic properly. Thus DPP-4 inhibitors are
crucial for the treatment of T2DM in China.
However, it has been observed, in some clinical trials
conducted in China, the efficacy of DPP-4 inhibitors is
weaker than that in trials conducted outside China [6].
It has been suspected that this phenomenon may be
caused by a higher placebo effect (i.e., differential HbA1c
response in the placebo arm). So far, no one has investi-
gated systematically whether this placebo effect truly ex-
ists. If this placebo effect exists, it is problematic for not
only the ongoing studies but also further studies. More-
over, this medical information should be considered as
an important factor for decision making in conducting
DPP-4 trials in China in the future.
Consequently, there is a critical need to investigate the
differential HbA1c response in the placebo arm in trials
conducted in China. To serve this need, we did a meta-
analysis to investigate HbA1c response in the placebo
arm in phase III placebo-control clinical trials of DPP-4
inhibitors. We concentrated on the HbA1c response in
the placebo arm in trials conducted in China. We also
included studies from other countries and compared
those conducted in China to those conducted in other
countries.
Methods
Search strategy and inclusion criteria
We searched EMBASE, PubMed, Google Scholar,
ClinicalTrials.gov and PharmaProject for phase III
placebo-control clinical trials of DPP-4 inhibitors in
T2DM until March 2016. The key words for searching
were sitagliptin, saxagliptin, vildagliptin, linagliptin, alo-
gliptin, Dipeptidyl peptidase-4 inhibitor and DPP-4. The
publications of these trials came from EMBASE, PubMed,
and Google. We also included those being completed with
results, but unpublished, trials at ClinicalTrials.gov. We
browsed the trial list of every drug in PharmaProject to
ensure completeness.
The meta-analysis included randomized placebo con-
trolled phase III clinical trials conducted in patients 18
years or older with T2DM on the following DPP-4 inhibi-
tors: Sitagliptin (FDA approved in 2006, CFDA approved
in 2009, marketed by Merck & Co. as Januvia), Saxagliptin
(FDA approved in 2009, CFDA approved in 2011, mar-
keted by Bristol-Myers Squibb as Onglyza), Vildagliptin
(EU approved in 2007, CFDA approved in 2011, marketed
by Novartis as Galvus), Linagliptin (FDA approved in
2011, CFDA approved in 2013, marketed by Eli Lilly Co
and Boehringer Ingelheim as Trajenta), Alogliptin (FDA
approved in 2013, CFDA approved in 2013, marketed by
Takeda Pharmaceutical Company as Nesina).
Trials included in this meta-analysis met the following
criteria: (1) Only randomized placebo controlled phase III
clinical trials are included, (2) DPP-4 inhibitor as mo-
nopoly or combination therapy is compared with placebo,
(3) patients should be treated for at least 12 weeks, (4)
HbA1c is the primary endpoint, (5) the trials were con-
ducted in China with independent results of Chinese pa-
tients or conducted outside China without Chinese patients.
Data extraction and quality evaluation
We extract characteristics and results of trials including
the following items: location, experimental drug, com-
bined drug, test duration, the number of patients in-
cluded, average age, gender, diabetes duration, baseline
HbA1c, and the change of HbA1c in control groups.
We used the scoring system developed by Jadad et al.
[7] to evaluate the quality of the publications. Ran-
domization, double-blinding, and description of withdraws
are considered. Possible scores range from 0 to 5.
Statistical analysis
The package Metafor [8] in R was used to conduct stat-
istical analysis for the HbA1c response in the placebo
arm. This package consists of a collection of functions
that allow the user to fit fixed-, random-, and mixed-
effects models and to carry out meta-regression analysis.
Weighted Mean change and 95 % confidence interval for
changes from baseline in HbA1c in the placebo control
groups were calculated. For studies in China, unless
there was heterogeneity, we would use a fixed-effects
model. Otherwise a random-effects model would be
used. When comparing trials in China with those out-
side China, a mixed-effects model was performed. We
use I2 to determine heterogeneity [9] and leave-one-out
to perform sensitivity analysis. Publication bias was ex-
amined by Egger’s regression test [10].
Results
Characteristics of studies
A total of 1632 papers and 217 trials were identified.
After careful review, 10 studies [6, 11–19] conducted in
China were included among which there were 3 unpub-
lished trials [12, 13, 17]. In addition, 56 studies [20–75]
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conducted outside China were included. Most of these tri-
als including patients coming from different countries,
while there were 17 trials [59–75] involving only Japanese
patients. There were a total of 8303 participants (mean
age 56, male 57 %) in placebo groups. Search results are
summarized in Fig. 1.
The summarized information on the included studies
is shown in Tables 1 and 2. Table 1 displays the informa-
tion of studies conducted on Chinese patients in China.
There are 4 trials for Sitagliptin, 3 trials for Vildagliptin,
2 trials for Linagliptin and 1trial for Alogliptin. A total
of 1634 patients with T2DM in the placebo groups were
included. Their average age is between 50 and 60 while
the average durations of diabetes are quite different.
Average baselines of HbA1c are above 8 %. The treat-
ment time of most studies is 24 weeks while Mohan [14]
has 18 weeks and NCT01289119 [17] has 16 weeks. Be-
sides, NCT01076088 [12] and NCT01289119 [17] both
have 3 placebo groups.
Table 2 shows the 56 trials conducted on non-Chinese
patients outside China. There are 21 trials for Sitagliptin,
13 trials for Vildagliptin, 9 trials for Linagliptin, 8 trials
for Alogliptin and 5 trials for Saxagliptin. A total of 6669
patients with T2DM in the placebo groups were in-
cluded. There is no significant difference in average age
between patients in Tables 1 and 2, respectively, whereas
the Japanese patients seem a little older than others. As
for the duration of diabetes, patients in studies using in-
sulin as the combination therapy suffered longer than
others. The baselines of HbA1c range from 7.30 % to
9.30 %, and the variation is greater than those in Table 1.
All the trials conducted in Japan treated patients for 12
weeks except Kadowaki 2013, and the treatment dur-
ation of most other studies in Table 2 is 24 weeks.
Differential HbA1c response in the placebo arm
We analyzed the placebo effect in all the trials, focusing
on HbA1c change from baseline in controlled groups.
Generally, placebo should not have a significant effect
on HbA1c, even if there was combination therapy. The
general HbA1c change from baseline in placebo con-
trolled groups should be close to 0. However, it has been
observed that there is a high placebo effect in some trials
conducted in China [6]. We focused on HbA1c change
Fig. 1 A flow diagram of the selection of eligible studies
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from baseline in placebo controlled groups in trials
conducted in China. We first summarized the HbA1c re-
sponse in the placebo arm in trials conducted in China
and then made a comparison to those conducted outside
China.
Among 10 randomized placebo-controlled phase III
clinical trials of DPP-4 inhibitors conducted in patients
with T2DM in China, NCT01076088 [12] and
NCT01289119 [17] have 3 placebo controlled groups
with different combination therapy respectively. Thus
totally 14 groups were included in the meta-analysis.
Since there was substantial heterogeneity, random-
effects model was performed. The weighted mean
change from baseline was calculated and forest plot was
drawn. Results are shown in Fig. 2. The results show
that HbA1c is declined by 0.42 % with a p-value less
than 0.001 in the placebo arm of randomized placebo
controlled phase III clinical trials of DPP-4 inhibitors
conducted in patients with T2DM in China. The 95 %
confidence interval is (-0.66 %, -0.18 %).
We noted that the heterogeneity index I2 of this model
is significantly large. Thus we performed a leave-one-out
sensitivity analysis to detect the influence of each study.
Each time we left one group out, then fitted the same
model. We got the summary estimates and I2 of 14
models with results shown in Fig. 3. We found that the
estimates of models that left out NCT01076088-2 [12]
or NCT01076088-3 [12] are significant different from
those in the full model that included all the 14 groups.
The other groups show less heterogeneity. In addition,
from Fig. 2, we see that the placebo effects of
NCT01076088-2 [12] and NCT01076088-3 [12] are
much higher than others, both larger than 1 %. In these
two groups, metformin was used as combination ther-
apy, patients’ baseline HbA1c were higher than average,
and there were no information about the duration of
diabetes. These might cause the significant difference in
HbA1c decline between the two studies and others.
To decrease the heterogeneity, we further performed a
random-effect model excluding these two groups. The
weighted mean change from baseline was calculated and
a forest plot was drawn. Results are shown in Fig. 4. In
this model, I2 declines to 71.63 %. We also performed a
leave-one-out sensitivity analysis on this model. While
leaving out some studies would decrease I2, the estimates
wouldn’t change much. The results based on the model
excluding NCT01076088-2 [12] and NCT01076088-3 [12]
indicate that, HbA1c in placebo controlled groups de-
clined by 0.26 % with 95 % confidence interval being
(-0.36 %, -0.16 %) and p-value less than 0.001 (Fig. 4).
Egger’s regression test shows there is no publication bias
(p-value is 0.802).
The results based on either of the two models (i.e., the
full model and the model excluding two heterogeneous
studies) show a significant placebo effect in the placebo
arm in the same direction as the DDP-4 inhibitor’s
effect. These results provide statistically significant
evidence that the placebo effect is not 0 in randomized
placebo controlled phase III clinical trials of DPP-4
inhibitors conducted in patients with T2DM in China.
Table 1 Trials conducted in China





















Yang [11] China Sitagliptin Metformin 198 55 55 7.30 8.50 -0.14 24 5
NCT01076088 [12] China Sitagliptin None 127 40 68 / 8.97 -0.59 24 /
Metformin 126 57 55 8.69 -1.29
Metformin 124 49 60 8.67 -1.56
NCT01177384 [13] China Sitagliptin Acarbose 189 57 51 / 8.08 -0.14 24 /
Mohan [14] China Sitagliptin / 82 51 60 1.70 8.60 -0.20 18 5
Pan [6] China Vildagliptin Metformin 144 54 46 5.15 8.01 -0.54 24 3
Yang [15] China Vildagliptin Glimepiride 136 59 58 6.90 8.70 -0.20 24 4
Zeng [16] China Linagliptin Metformin &
sulphonylurea
48 57 52 >5 8.13 0.08 24 3
NCT01289119 [17] China Alogliptin None 93 53 58 2.12 / -0.42 16 /
Metformin 98 53 49 5.33 -0.22
Pioglitazone 63 52 62 4.85 -0.25
Chen [18] China Linagliptin / 88 54 59 / 8.09 -0.25 24 4
Ning [19] China Vildagliptin Insulin 118 58.5 55 11.4 8.6 -0.22 24 5
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Table 2 Trials conducted outside China














Rosenstock [20] non-China Alogliptin Insulin 130 55 48 12.2 9.30 -0.13 26 5
Nauck [21] non-China Alogliptin Metformin 104 56 48 6.0 8.00 -0.10 26 5
Raz [22] non-China Sitagliptin / 103 55 63 4.7 8.00 0.12 18 4
Aschner [23] non-China Sitagliptin / 244 54 51 4.6 8.00 0.18 24 4
Hanefeld [24] non-China Sitagliptin / 111 56 63 3.3 7.60 0.12 12 4
Goldstein [25] non-China Sitagliptin Metformin 176 54 53 4.6 8.70 0.17 24 4
Charbonnel [26] non-China Sitagliptin Metformin 237 55 60 6.6 7.98 -0.02 24 4
Raz [27] non-China Sitagliptin Metformin 94 56 42 7.3 9.10 0.00 30 5
Rosenstock [28] non-China Sitagliptin Pioglitazone 178 57 58 6.1 8.02 -0.15 24 4
Hermansen [29] non-China Sitagliptin Glimepiride, Metformin 219 56 53 9.3 8.34 0.28 24 5
Vilsbøll [30] non-China Sitagliptin Insulin 319 57 53 12.0 8.60 0.00 24 5
Scott [31] non-China Sitagliptin / 125 55 62 4.8 7.90 0.23 12 5
Scott [32] non-China Sitagliptin Metformin 92 55 59 5.4 7.70 -0.22 18 4
Ristic [33] non-China Vildagliptin / 58 55 57 2.3 7.76 -0.13 12 3
Dejager [34] non-China Vildagliptin / 94 52 48 1.6 8.40 -0.30 24 4
Pi-Sunyer [35] non-China Vildagliptin / 92 52 54 2.5 8.50 0.00 24 4
Bosi [36] non-China Vildagliptin Metformin 130 55 53 6.2 8.30 0.20 24 3
Garber [37] non-China Vildagliptin Pioglitazone 138 55 51 4.8 8.70 -0.30 24 4
Garber [38] non-China Vildagliptin Glimepiride 144 58 58 7.8 8.50 0.07 24 5
Fonseca [39] non-China Vildagliptin Insulin 152 59 55 14.9 8.40 -0.20 24 4
Defronzo [40] non-China Saxagliptin Metformin 179 55 54 6.7 8.10 0.13 24 4
Del Prato [41] non-China Linagliptin / 167 54 47 / 8.00 0.25 24 4
Taskinen [42] non-China Linagliptin Metformin 177 57 57 / 8.02 0.15 24 4
Moses [43] non-China Sitagliptin Sulfonylurea, Metformin 212 55.4 46 8 8.4 -0.16 24 5
Laakso [44] non-China Linagliptin Glimepiride 120 66.6 63.4 / 8.1 -0.11 12 3
White [45] non-China Saxagliptin Metformin 84 56.6 52.3 6.2 7.97 -0.22 12 5
Moses [46] non-China Saxagliptin Sulfonylurea, Metformin 127 56.8 57.8 / 8.2 -0.08 24 4
Bajaj [47] non-China Linagliptin Metformin, Pioglitazone 89 55.2 55.1 / 8.47 -0.27 24 4
Fonseca [48] non-China Sitagliptin Metformin, Pioglitazone 153 56.4 62.8 10.2 8.6 -0.4 26 5
Kothny [49] non-China Vildagliptin Insulin 221 59.1 52 13.2 8.8 -0.1 24 4
Dobs [50] non-China Sitagliptin Metformin, Osiglitazone 88 54.8 60 9.4 8.7 -0.3 18 5















Table 2 Trials conducted outside China (Continued)
Barnett [52] non-China Linagliptin / 73 56.7 43.4 / 8.1 0.21 18 5
Forst [53] non-China Linagliptin Metformin 70 60.1 62 6.2 8.4 0.24 12 4
Nowicki [54] non-China Saxagliptin / 83 66.2 48.2 18.2 8.09 -0.44 12 5
Gomis [55] non-China Linagliptin Pioglitazone 128 57.1 65.4 / 8.58 -0.56 24 4
Hollander [56] non-China Saxagliptin Thiazolidinedione 180 54.1 46.2 5.1 8.2 -0.3 24 4
Pratley [57] non-China Alogliptin Glyburide 99 57.1 51.5 7.7 8 0.01 26 4
Pratley [58] non-China Vildagliptin / 26 52.8 50 3.5 8.1 0 12 5
Nonaka [59] Japan Sitagliptin / 76 55 66 4.1 7.70 0.41 12 5
Kikuchi [60] Japan Vildagliptin / 20 62 55 7.2 7.30 0.28 12 4
Iwamoto [61] Japan Sitagliptin / 73 60 69 6.4 7.74 0.28 12 4
Kikuchi [62] Japan Vildagliptin Glimepiride 100 60 69 9.8 8.00 -0.06 12 4
Kaku [63] Japan Alogliptin Pioglitazone 115 60 66 6.7 7.92 -0.19 12 4
Kashiwagi [64] Japan Sitagliptin Pioglitazone 68 59 72 7.6 8.00 0.40 12 5
Seino [65] Japan Alogliptin Voglibose 75 62 64 7.5 8.12 0.04 12 5
Kawamori [66] Japan Linagliptin / 80 60 71 5.0 7.95 0.63 12 4
Seino [67] Japan Alogliptin Metformin 100 52 72 6.0 8.00 0.21 12 5
Seino [68] Japan Alogliptin Sulfonylurea 103 60 69 9.4 8.62 0.35 12 4
Kadowaki [69] Japan Sitagliptin Metformin 72 57 68 7.3 8.40 0.30 12 5
Kaku [70] Japan Alogliptin Insulin 89 62 53 14.5 8.43 -0.31 12 4
Odawara [71] Japan Vildagliptin Metformin 70 58 69 7.0 8.00 -0.10 12 4
Hirose [72] Japan Vildagliptin Insulin 75 60.1 71.2 12.9 8.1 -0.11 12 5
Tajima [73] Japan Sitagliptin Voglibose 63 58.6 71.5 / 7.9 0.2 12 4
Kadowaki [74] Japan Sitagliptin Insulin 128 60.2 58.4 14 8.9 0.3 16 4















Considering minimizing the impact of heterogeneity
in the analysis, the analysis based on the model ex-
cluding the two heterogeneous studies may be more
reliable. Thus, for future reference, we may conclude
that placebo decreases HbA1c by 0.26 % (95 % CI
[-0.36 %, -0.16 %] and p-value less than 0.001) gener-
ally in trials conducted in Chinese patients in China
(Fig. 4).
We compared trials conducted in China with those
outside China using a mixed-effects model. Table 3
shows the analysis results. The model is fitted with loca-
tion as a moderator. We treat location as a binary vari-
able, 1 for China and 0 for non-China.
The intercept, 0.015 % (95 % CI [-0.05 %, 0.08 %],
p-value is 0.637), shows that the HbA1c response in
the placebo arm of trials conducted outside China
(location = 0) is close to 0. The coefficient for loca-
tion, -0.273 % (95 % CI [-0.42 %, -0.13 %], p-value is
less than 0.001), shows a large difference of HbA1c
response in the placebo arm between trials conducted
in China (location = 1) and those outside China. The
difference is statistically significant.
In addition, as trials conducted in Japan have shorter
test duration and in some trials placebo significantly in-
creased HbA1c, we performed another model treating
Japan as a separate group. Table 4 shows the analysis
Fig. 2 Forest plot for all placebo groups in trials conducted in China
Fig. 3 Results of leave-one-out sensitivity analysis
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results. The model is fitted with location as a moderator,
1 for China, 2 for Japan and 0 for others.
This model shows that the HbA1c response in the
placebo arm in trials conducted in countries except
China and Japan was close to 0 (-0.055 with p-value
0.118). Trials conducted in Japan had a reverse
placebo effect which means placebo increased HbA1c
by 0.22 % (95 % CI [0.10 %, 0.34 %], p-value is less
than 0.001). Finally, the model shows the difference
of HbA1c response in the placebo arm between trials
conducted in China and other countries except Japan
is -0.203 % (95 % CI [-0.35 %, -0.06 %]) with a p-value of
0.005. The difference is also statistically significant.
Discussion
DPP-4 inhibitors are an important class of oral anti-
hyperglycemic agents [2–4]. Until now five DPP-4
inhibitors, sitagliptin, saxagliptin, vildagliptin, lina-
gliptin, alogliptin, have been approved for marketing
by CFDA. A large number of trials have been conducted
in China determining the efficacy of these drugs in Chin-
ese patients. For example, in a 24-week, randomized,
double-blind, placebo-controlled study with 438 Chinese
T2DM patients, Pan [6] discovered that the adjusted mean
change in HbA1c at endpoint was −1.05 ± 0.08 %, −0.92 ±
0.08 % and −0.54 ± 0.08 % in patients receiving vilda-
gliptin 50 mg bid, 50 mg qd and placebo, respectively.
In this study, the 95 % confidence interval for the
HbA1c response in the placebo arm is (-0.70, -0.38),
indicating an HbA1 decline in the placebo arm. Simi-
lar HbA1 decline was discovered in a fair number of
other trials in Chinese patients such as NCT01076088
[12] and NCT01289119 [17]. There are a few trials
with the 95 % confidence interval of HbA1 in the pla-
cebo arm covering 0 such as (-0.28, 0) in Yang [11]
and (-0.16, 0.32) in Zeng [16]. However, no trial has
shown a significant HbA1c increase in the placebo
arm in trials with Chinese patients. Therefore, there
is a suspicion that there is an HbA1c decline in the
placebo arm of DPP-4 inhibitor clinical trials con-
ducted in China. Is that suspicion true? No one has
addressed this question systematically yet. Therefore,
in this article, we use a systematic meta-analysis ap-
proach to address this question.
The meta-analysis shows that, HbA1c in the placebo
arm declined by 0.26 % (95 % CI [-0.36 %, -0.16 %] and
p-value less than 0.001) in trials of DPP-4 inhibitors
conducted in patients with T2DM in China, whereas
Fig. 4 Forest plot for placebo groups in trials conducted in China after excluding two extreme groups
Table 3 Mixed-effects model 1 (k = 68)
Standard error z value p value Lower 95 % confidence interval Upper 95 % confidence interval
Intercept 0.015 0.031 0.472 0.637 -0.047 0.076
Factor(location)1 -0.273 0.076 -3.612 <.001 -0.421 -0.125
The model is fitted with location as moderator. Location was regarded as binary variable, 1 for China and 0 for non-China
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the placebo effect of those conducted outside China is
close to 0. The difference of HbA1c in the placebo arm
between trials conducted in China and outside China
is -0.273 % (95 % CI [-0.42 %, -0.13 %], p-value is less than
0.001). After excluding trials conducted in Japan, the
difference is -0.203 % (95 % CI [-0.35 %, -0.06 %]) with a
p-value of 0.005. They are both statistically significant.
Therefore, after we investigated the placebo effect of
randomized placebo controlled phase III clinical trials
of DPP-4 inhibitors conducted in patients with T2DM
in China, we concluded that there was statistically
significant difference in response in the placebo arm
between trials conducted in China and outside China.
This difference of HbA1c decline in the placebo arm
should be taken into account in future studies in
China.
There may be various reasons for this high placebo
effect. However, what these reasons exactly are is un-
known. Although the investigation of these reasons is
not the purpose in this article, we have the following
two major guesses. First, the practical process of these
trials could cause a bias. Most of the trials provided the
participants the significant benefit to obtain more
resource of medical care, esp. in China. Because of no
established PCP system, low awareness of diabetes man-
agement, China has most diabetes patients in the world
[5] but much lower health workers/patient ratio than
Europe, USA and Japan [76]. Clinical trials could have
obvious impact on management of diabetes, and thus
cause better blood glucose control even in placebo arm.
Second, Traditional Chinese Medicine (TCM) could play
role. There is evidence that the use of some TCM herbs
can reduce hyperglycemia [77]. Among these herbs
many are used commonly in diet or drinks. Normally in
study protocol, herbs in diet were not clearly inhibited.
Other reasons may include life style and culture that are
unique in China.
The results on the placebo effect on other countries
may also provide values for future trials and medical
interpretation. For example, clinical trials conducted in
Japan had a statistically significant reverse placebo effect,
which may be important information for conducting
future DDP-4 trials as well as for interpreting trial re-
sults in Japan.
Conclusions
The meta-analysis in the article demonstrates that there
are significant differences in response in the placebo
group of DPP-4 trials conducted in China compared to
those conducted outside of China. This difference may
give some clue to why the efficacy of these drugs is less
statistically significant in trials conducted in China.
More importantly, this difference in response in the
placebo group should be taken into account for future
DDP-4 trials conducted in China. In addition, the dif-
ference in placebo should be carefully considered by
medical decision makers when future DPP-4 studies are
conducted in China.
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Table 4 Mixed-effects model 2 (k = 68)
Standard error z value p value Lower 95 % confidence interval Upper 95 % confidence interval
Intercept -0.055 0.035 -1.565 0.118 -0.123 0.014
Factor(location)1 -0.203 0.073 -2.803 0.005 -0.346 -0.061
Factor(location)2 0.22 0.062 3.546 <.001 0.098 0.342
The model is fitted with location as moderator. Location was regarded as categorical variable, 1 for China, 2 for Japan and 0 for others
He et al. BMC Pharmacology and Toxicology  (2016) 17:40 Page 9 of 11
References
1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE.
Global estimates of diabetes prevalence for 2013 and projections for 2035.
Diabetes Res Clin Pract. 2014;103:137–49.
2. Campbell RK. Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of
Oral Agents for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother.
2006;41:51–60.
3. Yousefzadeh P, Yousefzadeh P, Wang X, Wang X. The Effects of Dipeptidyl
Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes
Mellitus. J Diabetes Res. 2013;2013:1–6.
4. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the
management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes
Obes. 2007;14:98–107.
5. China Diabetes Society. Guideline of Prevention and Treatment for T2DM in
China (2013). Chin J Diabetes Mellitus. 2014;6:447–98.
6. Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G. Efficacy and
tolerability of vildagliptin as add‐on therapy to metformin in Chinese patients
with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:737–44.
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ,
McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is
blinding necessary? Control Clin Trials. 1996;17:1–12.
8. Viechtbauer W. metafor: Meta-Analysis Package for R. http://www.metafor-
project.org/doku.php. Accessed Sept 2014.
9. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Statist Med. 2002;21:1539–58.
10. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected
by a simple, graphical test. BMJ. 1997;315:629–34.
11. Yang W, Guan Y, Shentu Y, Li Z, Johnson Levonas AO, Engel SS, Kaufman KD,
Goldstein BJ, Alba M. The addition of sitagliptin to ongoing metformin therapy
significantly improves glycemic control in Chinese patients with type 2
diabetes*†. J Diabetes. 2012;4:227–37.
12. Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-
0431-121). https://clinicaltrials.gov/ct2/show/NCT01076088. Accessed Aug 2014.
13. Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in
Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy
(MK-0431-130). http://clinicaltrials.gov/ct2/show/NCT01177384. Accessed Aug 2014.
14. Mohan V, Yang W, Son H-Y, Xu L, Noble L, Langdon RB, Amatruda JM,
Stein PP, Kaufman KD. Efficacy and safety of sitagliptin in the treatment of
patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin
Pract. 2009;83:106–16.
15. Yang W, Xing X, Lv X, Li Y, Ma J, Yuan G, Sun F, Wang W, Woloschak M,
Lukashevich V, Kozlovski P, Kothny W. Vildagliptin added to sulfonylurea
improves glycemic control without hypoglycemia and weight gain in
Chinese patients with type 2 diabetes mellitus. J Diabetes. 2015;7:174–81.
16. Zeng Z, Yang J-K, Tong N, Yan S, Zhang X, Gong Y, Woerle H-J. Efficacy and
safety of linagliptin added to metformin and sulphonylurea in Chinese
patients with type 2 diabetes: a sub-analysis of data from a randomised
clinical trial. Curr Med Res Opin. 2013;29:921–9.
17. Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes.
http://clinicaltrials.gov/ct2/show/NCT01289119. Accessed Aug 2014.
18. Chen Y, Ning G, Wang C, Gong Y, Patel S, Zhang C, Izumoto T, Woerle H-J,
Wang W. Efficacy and safety of linagliptin monotherapy in Asian patients
with inadequately controlled type 2 diabetes mellitus: A multinational,
24-week, randomized, clinical trial. J Diabetes Investig. 2015;6:692–8.
19. Ning G, Wang W, Li L, Ma J, Lv X, Yang M, Wang W, Woloschak M, Lukashevich V,
Kothny W. Vildagliptin as add-on therapy to insulin improves glycemic control
without increasing risk of hypoglycemia in Asian, predominantly Chinese,
patients with type 2 diabetes mellitus. J Diabetes. 2016;8:345–53.
20. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin
added to insulin therapy in patients with type 2 diabetes reduces HbA1c
without causing weight gain or increased hypoglycaemia. Diabetes Obes
Metab. 2009;11:1145–52.
21. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of
adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy
in patients with type 2 diabetes inadequately controlled with metformin
monotherapy: a multicentre, randomised, double-blind, placebo-controlled
study. Int J Clin Pract. 2009;63:46–55.
22. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, Group SS0.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as
monotherapy in patients with type 2 diabetes mellitus. Diabetologia.
2006;49:2564–71.
23. Aschner P, Kipnes MS, Lunceford JK. Effect of the dipeptidyl peptidase-4
inhibitor sitagliptin as monotherapy on glycemic control in patients with
type 2 diabetes. Diabetes Care. 2006;29:2632–37.
24. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP, investigators
OBOTSS0. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for
the treatment of patients with type 2 diabetes. Curr Med Res Opin.
2007;23:1329–39.
25. Goldstein BJ, Feinglos MN, Lunceford JK. Effect of initial combination therapy
with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic
control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–87.
26. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and Safety of the
Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin
Therapy in Patients With Type 2 Diabetes Inadequately Controlled With
Metformin Alone. Dia Care. 2006;29:2638–43.
27. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB,
Stein PP, ALBA M. Efficacy and safety of sitagliptin added to ongoing
metformin therapy in patients with type 2 diabetes. Curr Med Res Opin.
2008;24:537–50.
28. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the
dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone
therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized,
double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–68.
29. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and
safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with
type 2 diabetes mellitus inadequately controlled on glimepiride alone or on
glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–45.
30. Vilsbøll T, Rosenstock J, Yki Järvinen H, Cefalu WT, Chen Y, Luo E, Musser B,
Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L. Efficacy and
safety of sitagliptin when added to insulin therapy in patients with type 2
diabetes. Diabetes Obes Metab. 2010;12:167–77.
31. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl
peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients
with type 2 diabetes. Int J Clin Pract. 2007;61:171–80.
32. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when
added to ongoing metformin therapy in patients with type 2 diabetes*.
Diabetes Obes Metab. 2008;10:959–69.
33. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with
dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes:
vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692–8.
34. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-na ï ve
patients with type 2 diabetes: a 24-week, double-blind, randomized,
placebo-controlled, multiple-dose study. Horm Metab Res. 2007.
35. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of
vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
Diabetes Res Clin Pract. 2007;76:132–8.
36. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of
Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2
Diabetes Inadequately Controlled With Metformin. Dia Care. 2007;30:890–5.
37. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in
combination with pioglitazone improves glycaemic control in patients with
type 2 diabetes failing thiazolidinedione monotherapy: a randomized,
placebo-controlled study*. Diabetes Obes Metab. 2007;9:166–74.
38. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP,
Couturier A, Baron MA. Effects of vildagliptin on glucose control in patients
with type 2 diabetes inadequately controlled with a sulphonylurea*.
Diabetes Obes Metab. 2008;10:1047–56.
39. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition
of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
Diabetologia. 2007;50:1148–55.
40. DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S,
Chen RS, Group FTS0S. The Efficacy and Safety of Saxagliptin When Added
to Metformin Therapy in Patients With Inadequately Controlled Type 2
Diabetes With Metformin Alone. Dia Care. 2009;32:1649–55.
41. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA.
Effect of linagliptin monotherapy on glycaemic control and markers of
β-cell function in patients with inadequately controlled type 2 diabetes:
a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–67.
42. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ.
Safety and efficacy of linagliptin as add-on therapy to metformin in patients
with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Diabetes Obes Metab. 2011;13:65–74.
He et al. BMC Pharmacology and Toxicology  (2016) 17:40 Page 10 of 11
43. Moses RG, Round E, Shentu Y, Golm GT, O’neill EA, Gantz I, Engel SS,
Kaufman KD, Goldstein BJ. A randomized clinical trial evaluating the safety
and efficacy of sitagliptin added to the combination of sulfonylurea and
metformin in patients with type 2 diabetes mellitus and inadequate
glycemic control. J Diabetes. 2015. doi:10.1111/1753-0407.12351.
44. Laakso M, Rosenstock J, Groop PH, Barnett AH. Treatment with the
dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by
glimepiride in patients with type 2 diabetes with moderate to severe renal
impairment: a 52-week, randomized, double-blind clinical trial. Diabetes
Care. 2015;38:e15–7.
45. White JL, Buchanan P, Li J, Frederich R. A randomized controlled trial of the
efficacy and safety of twice-daily saxagliptin plus metformin combination
therapy in patients with type 2 diabetes and inadequate glycemic control
on metformin monotherapy. BMC Endocr Disord. 2014;14:1.
46. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M,
Fisher SA. A randomized controlled trial of the efficacy and safety of saxagliptin as
add-on therapy in patients with type 2 diabetes and inadequate glycaemic
control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014;16:443–50.
47. Bajaj M, Gilman R, Patel S, Kempthorne Rawson J, Lewis D’Agostino D,
Woerle HJ. Linagliptin improved glycaemic control without weight gain or
hypoglycaemia in patients with Type 2 diabetes inadequately controlled by
a combination of metformin and pioglitazone: a 24-week randomized,
double-blind study. Diabet Med. 2014;31:1505–14.
48. Fonseca V, Staels B, Morgan II JD, Shentu Y, Golm GT, Johnson Levonas AO,
kaufman KD, Goldstein BJ, Steinberg H. Efficacy and safety of sitagliptin
added to ongoing metformin and pioglitazone combination therapy in a
randomized, placebo-controlled, 26-week trial in patients with type 2
diabetes. J Diabetes Complicat. 2013;27:177–83.
49. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved
glycaemic control with vildagliptin added to insulin, with or without
metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab.
2013;15:252–7.
50. Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, Hill JS,
Chen Y, Golm GT, Langdon RB, Williams Herman DE, Kaufman KD, Amatruda
JM, Ferreira JCA. Efficacy and safety of sitagliptin added to ongoing
metformin and rosiglitazone combination therapy in a randomized
placebo-controlled 54-week trial in patients with type 2 diabetes. J
Diabetes. 2013;5:68–79.
51. Lewin AJ, Arvay L, Liu D, Patel S, Eynatten Von M, Woerle H-J. Efficacy and
Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients
With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week,
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Clin Ther.
2012;34:1909–19. e15.
52. Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, Eynatten M, Woerle HJ.
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is
inappropriate: an 18-week randomized, double-blind, placebo-controlled
phase III trial with a 34-week active-controlled extension. Diabetes Obes
Metab. 2012;14:1145–54.
53. Forst T, Uhlig Laske B, Ring A, Graefe Mody U, Friedrich C, Herbach K, Woerle HJ,
Dugi KA. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe
and efficacious in combination with metformin in patients with inadequately
controlled Type 2 diabetes. Diabet Med. 2010;27:1409–19.
54. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause Nilsson I.
Saxagliptin improves glycaemic control and is well tolerated in patients
with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab.
2011;13:523–32.
55. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of
initial combination therapy with linagliptin and pioglitazone in patients
with inadequately controlled type 2 diabetes: a randomized, double-blind,
placebo-controlled study. Diabetes Obes Metab. 2011;13:653–61.
56. Hollander P, Li J, Allen E, Chen R. Saxagliptin Added to a Thiazolidinedione
Improves Glycemic Control in Patients with Type 2 Diabetes and
Inadequate Control on Thiazolidinedione Alone. J Clin Endocrinol Metab.
2011;94:4810–9.
57. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the
dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes
inadequately controlled by glyburide monotherapy. Diabetes Obes Metab.
2009;11:167–76.
58. Pratley RE, Holmes D. Twelve − week Monotherapy with the DPP− 4
Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2
Diabetes. Horm Metab Res. 2006.
59. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H,
Hirayama Y, Ahmed T, Davies MJ, Stein PP. Efficacy and safety of sitagliptin
monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin
Pract. 2008;79:291–8.
60. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin
dose-dependently improves glycemic control in Japanese patients with
type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–40.
61. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Ferreira JCA, Amatruda
J. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese
patients with type 2 diabetes mellitus. Endocr J. 2010;57:383–94.
62. Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N,
Inaba Y, Goodman M. Efficacy and tolerability of vildagliptin as an add-on to
glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res
Clin Pract. 2010;89:216–23.
63. Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y. Efficacy and safety of
alogliptin added to pioglitazone in Japanese patients with type 2 diabetes:
a randomized, double-blind, placebo-controlled trial with an open-label
long-term extension study. Diabetes Obes Metab. 2011;13:1028–35.
64. Kashiwagi A, Kadowaki T, Tajima N, Nonaka K, Taniguchi T, Nishii M, Ferreira JCA,
Amatruda JM. Sitagliptin added to treatment with ongoing pioglitazone for up
to 52weeks improves glycemic control in Japanese patients with type 2
diabetes. J Diabetes Investig. 2011;2:381–90.
65. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in
Japanese patients with type 2 diabetes: a randomized, double-blind,
placebo-controlled trial with an open-label, long-term extension. Curr Med
Res Opin. 2011;27:21–9.
66. Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A,
Gong Y, von Eynatten M, Woerle HJ, Dugi KA. Linagliptin monotherapy
provides superior glycaemic control versus placebo or voglibose with
comparable safety in Japanese patients with type 2 diabetes: a randomized,
placebo and active comparator-controlled, double-blind study. Diabetes
Obes Metab. 2012;14:348–57.
67. Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of
alogliptin added to metformin in Japanese patients with type 2 diabetes: a
randomized, double-blind, placebo-controlled trial with an open-label,
long-term extension study. Diabetes Obes Metab. 2012;14:927–36.
68. Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added
to sulfonylurea in Japanese patients with type 2 diabetes: A randomized,
double-blind, placebo-controlled trial with an open-label, long-term
extension study. J Diabetes Investig. 2012;3:517–25.
69. Kadowaki T, Tajima N, Odawara M, Nishii M, Taniguchi T, Ferreira JCA.
Addition of sitagliptin to ongoing metformin monotherapy improves
glycemic control in Japanese patients with type 2 diabetes over 52 weeks.
J Diabetes Investig. 2013;4:174–81.
70. Kaku K, Mori M, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin
added to insulin in Japanese patients with type 2 diabetes: a randomized,
double-blind, 12-week, placebo-controlled trial followed by an open-label,
long-term extension phase. Expert Opin Pharmacother. 2014;15:2121–30.
71. Odawara M, Hamada I, Suzuki M. Efficacy and Safety of Vildagliptin as
Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Ther. 2014;5:169–81.
72. Hirose T, Suzuki M, Tsumiyama I. Efficacy and Safety of Vildagliptin as an
Add-on to Insulin with or without Metformin in Japanese Patients with
Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
Diabetes Ther. 2015;6:559–71.
73. Tajima N, Kadowaki T, Okamoto T, Sato A, Okuyama K, Minamide T,
Arjona Ferreira JC. Sitagliptin added to voglibose monotherapy improves
glycemic control in patients with type 2 diabetes. J Diabetes Investig.
2013;4:595–604.
74. Kadowaki T, Tajima N, Odawara M, Minamide T, Kawashima M, Yanagida D,
Okamoto T, Ferreira JCA. Efficacy and safety of sitagliptin add-on therapy in
Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int.
2013;4:160–72.
75. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Ferreira JCA. Addition
of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2
diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011;
2:32–44.
76. World Health Organization. World Health Statistics 2015. 2015.
77. Xie W, Zhao Y, Zhang Y. Traditional Chinese Medicines in Treatment of
Patients with Type 2 Diabetes Mellitus. Evid Based Complement Alternat
Med. 2011;2011:1–13.
He et al. BMC Pharmacology and Toxicology  (2016) 17:40 Page 11 of 11
